MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pntd.0001289

Медицинская библиотека · PLoS neglected tropical diseases · 2011

Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

Sur Dipika, Kanungo Suman, Sah Binod, Manna Byomkesh, Ali Mohammad, Paisley Allison M, Niyogi Swapan K, Park Jin Kyung, Sarkar Banawarilal, Puri Mahesh K, Kim Deok Ryun, Deen Jacqueline L, Holmgren Jan, Carbis Rodney, Rao Raman, Nguyen Thu Van, Han Seung Hyun, Attridge Stephen, Donner Allan, Ganguly Nirmal K, Bhattacharya Sujit K, Nair G Balakrish, Clemens John D, Lopez Anna Lena

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.

METHODS/PRINCIPAL FINDINGS: We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen of a low-cost killed whole cell OCV in residents 1 year of age and older living in 3,933 clusters in Kolkata, India. The primary endpoint was culture-proven Vibrio cholerae O1 diarrhea episodes severe enough to require treatment in a health care facility. Of the 66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients), 38 vaccinees and 128 placebo-recipients developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%CI lower bound = 53%, p<0.001). Vaccine protection during the third year of follow-up was 65% (one-sided 95%CI lower bound = 44%, p<0.001). Significant protection was evident in the second year of follow-up in children vaccinated at ages 1-4 years and in the third year in older age groups.

CONCLUSIONS/SIGNIFICANCE: The killed whole-cell OCV conferred significant protection that was evident in the second year of follow-up in young children and was sustained for at least three years in older age groups. Continued follow-up will be important to establish the vaccine's duration of protection.

TRIAL REGISTRATION: ClinicalTrials.gov NCT00289224.

Для цитирования: Sur Dipika, Kanungo Suman, Sah Binod, Manna Byomkesh, Ali Mohammad, Paisley Allison M, Niyogi Swapan K, Park Jin Kyung, Sarkar Banawarilal, Puri Mahesh K, Kim Deok Ryun, Deen Jacqueline L, Holmgren Jan, Carbis Rodney, Rao Raman, Nguyen Thu Van, Han Seung Hyun, Attridge Stephen, Donner Allan, Ganguly Nirmal K, Bhattacharya Sujit K, Nair G Balakrish, Clemens John D, Lopez Anna Lena. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.. PLoS neglected tropical diseases. 2011. DOI: 10.1371/journal.pntd.0001289.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.